Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis

por Liu, Kun, Zhu, Youwen, Zhu, Hong
Publicado 2023

Treatment‐related adverse events of antibody–drug conjugates in clinical trials: A systematic review and meta‐analysis

por Zhu, Youwen, Liu, Kun, Wang, Kailing, Zhu, Hong
Publicado 2022

The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial

por Zhu, Youwen, Liu, Kun, Cao, Hui, Zhu, Hong
Publicado 2023

Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer: a cost-effectiveness analysis

por Zhu, Youwen, Liu, Kun, Zhu, Hong, Wu, Haijun
Publicado 2023

Vascular Endothelial Growth Factor Receptor Inhibitors in Chinese Patients With Advanced Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Network Meta-Analysis and Co...

por Zhu, Youwen, Liu, Kun, Wang, Kailing, Peng, Libo
Publicado 2022

Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis

por Zhu, Youwen, Liu, Kun, Qin, Qun, Zhu, Hong
Publicado 2023

First-line Immuno-chemotherapy for extensive-stage small-cell lung cancer: A network meta-analysis and cost-effectiveness analysis

por Zhu, Youwen, Liu, Kun, Yang, Qiuping, Zeng, Manting, Peng, Libo
Publicado 2023

Comparative efficacy and safety of novel immuno-chemotherapy for extensive-stage small-cell lung cancer: a network meta-analysis of randomized controlled trial

por Zhu, Youwen, Liu, Kun, Zhu, Hong, Cao, Hui, Zhou, Yangying
Publicado 2023

Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis

por Zhu, Youwen, Liu, Kun, Wang, Min, Wang, Kailing, Zhu, Hong
Publicado 2022

Trastuzumab deruxtecan versus chemotherapy for patients with HER2-low advanced breast cancer: A US-based cost-effectiveness analysis

por Zhu, Youwen, Liu, Kun, Zhu, Xiaolu, Qin, Qun, Zhu, Hong
Publicado 2022

Chemo-Immunotherapy Regimes for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis

por Zhu, Youwen, Liu, Kun, Ding, Dong, Wang, Kailing, Liu, Xiaoting, Tan, Xiao
Publicado 2022

First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis

por Zhu, Youwen, Hu, Huabin, Ding, Dong, Li, Shuosha, Liao, Mengting, Shi, Yin, Huang, Jin
Publicado 2021

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer

por Hu, Huabin, She, Longjiang, Liao, Mengting, Shi, Yin, Yao, Linli, Ding, Dong, Zhu, Youwen, Zeng, Shan, Carbone, David P., Huang, Jin
Publicado 2020